Down-regulation of TGF-β1 production restores immunogenicity in prostate cancer cells

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 519-525

  Matthews, E ^a   Yang, T ^a   Janulis, L ^a   Goodwin, S ^a   Kundu, S D ^a   Karpus, W J ^a   Lee, C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Host tumour interaction; Immunogenicity; Rat prostate cancer; TGF expression; Tumour incidence

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1; TRITIUM;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INCIDENCE; CONTROLLED STUDY; DNA SEQUENCE; DNA SYNTHESIS; DOWN REGULATION; GENETIC TRANSFECTION; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

EID: 0033930877     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1257     Document Type: Article

References (21)

1. Barrack ER (1997) TGF-β in prostate cancer: A growth inhibitor that can enhance tumourigenicity. Prostate 31: 61-70
2. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF and Ross R (1990) TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63: 515-524
3. Bender FE, Douglas LW and Dramer A (1982) Statistical methods for food and agriculture, pp. 887-107. The AVI Publishing Co Inc: Westport, CT, USA
4. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I and Sobol RE (1996) Eradication of established intracranial ral gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914
5. Gomella LG, Sargent ER, Wade TP, Angland P, Lineham WM and Kasid BA (1992) Expression of transforming growth faclor-α in normal human adult kidney and enhanced expression of transforming growth factor-α and β1 in renal cell carcinoma. Cancer Res 49: 6972-6975
6. Isaacs JT, Yu GW and Coffey DS (1981) The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: The MATLyLu tumour. Invest Urol 9: 20-23
7. Isaacs JT, Isaacs WB, Feitz WF and Scheres J (1986) Establishment and characlerization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281
8. Janik P, Braind P and Hartman NP (1975) The effects of estrogen-progcsterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumours. Cancer Res 35: 3698-3704
9. Karpus WJ and Swanborg RH (1991) CD4+ supporessor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-β. J Immunol 146: 1163-1168
10. Laiho M, DeCaprio JA, Ludlow JW, Livinston DM and Massague J (1990) Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185
11. Letterio JJ and Roberts AB (1998) Regulation of immune responses by TGF-β. Annu Rev Immunol 16: 137-161
12. Morton DM and Barrack ER (1995) Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602
13. Pietenpol JA, Holt JT, Stein RW and Moses HL (1990) Transforming growth factor β1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci USA 87: 3758-3762
14. Shaw MW, Rubenstein M, Dubin A, McKiel CF and Guinan PD (1987) Effect of cyclophosphamide on leukocytic subset distributions in rats carrying the Dunning R3327-MAT-Lylu prostatic adenocarcinoma. Prostate 11: 117-125
15. Sherman LA and Chattopadhyay S (1993) The molecular basis of allorecognition. Ann Rev Immunol 11: 385-402
16. Smolev JK, Heston WDW, Scott WW and Coffey DS (1977) Characterization of the Dunning R3327H prostatic adenocarcinoma: An appropriate animal model for prostate cancer. Cancer Treat Rep 61: 273-287
17. Steele RGD and Torrie JH (1960) Principles and procedures of statistics. McGraw-Hill Book Co Inc: New York
18. Steiner MS and Barrack ER (1992) Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 6: 15-25
19. Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Ganshacher B and Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumour vaccines. Cancer Res 54: 1760-1765
20. Welch DR, Fabra A and Nakajima M (1990) Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678-7682
21. Yang EY and Moses HL (1990) Transforming growth factor-β1-induced changes on cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111: 731-741